複合性局所疼痛症候群の世界市場－市場の洞察、疫学、市場予測（～2032年）

当レポートでは、世界の複合性局所疼痛症候群市場について調査分析し、市場概要、上市されている製品、市場分析など、体系的な情報を提供しています。

目次

第1章 主な洞察

第2章 レポートのイントロダクション

第3章 複合性局所疼痛症候群市場概要：クラス別

• 市場シェア（%）の複合性局所疼痛症候群の分布（2019年）
• 市場シェア（%）の複合性局所疼痛症候群の分布（2032年）

第4章 複合性局所疼痛症候群のエグゼクティブサマリー

• 重要な出来事

第5章 疫学と市場調査手法

第6章 疾患の背景と概要

• イントロダクション
• 分類
• 兆候と症状
• 臨床症状
• ナチュラルコース
  • ステージ
• 病態生理学

第7章 複合性局所疼痛症候群の診断

• 調査
  • IASP診断基準
• イメージング技術
• 非侵襲的イメージング技術
• サーモグラフィ
• 汗腺機能検査
• 神経生理学的検査
• 検査
• 鑑別診断
• 複合性局所疼痛症候群の診断ガイドライン
  • 複雑性局所疼痛症候群：実用的な診断と治療のガイドライン、第5版（2022年）
  • 成人の複合性局所疼痛症候群の一次医療および二次医療における診断、紹介、および管理に関する英国のガイドライン
  • 日本の複合性局所疼痛症候群診断基準

第8章 複合性局所疼痛症候群の治療と管理

• 治療ガイドライン
  • 複雑性局所疼痛症候群：実用的な診断と治療のガイドライン、第5版－米国
  • 成人の複合性局所疼痛症候群の一次医療および二次医療における診断、紹介、および管理に関する英国のガイドライン

第9章 疫学と患者数

• 主な調査結果
• 仮定と根拠
• 疫学シナリオ：主要7ヶ国
  • 主要7ヶ国の複合性局所疼痛症候群の有病率の合計
  • 主要7ヶ国の複合性局所疼痛症候群の診断された有病率の総数
  • 主要7ヶ国の複合性局所疼痛症候群の性別特有の診断された有病率
  • 主要7ヶ国の複合性局所疼痛症候群の年齢別の診断された有病率
  • 主要7ヶ国の複合性局所疼痛症候群のタイプ固有の診断された有病率
  • 主要7ヶ国の複合性局所疼痛症候群の重症度別の診断された有病率
  • 主要7ヶ国の複合性局所疼痛症候群を治療した症例
• 米国の疫学
• EU4ヶ国および英国の疫学
• 日本の疫学

第10章 ペイシェントジャーニー

第11章 複合性局所疼痛症候群臨床試験における主要評価項目

第12章 新規治療薬

• 主要クロス競合
• 低用量ナルトレキソン（LDN）：Soin Therapeutics
  • 製品説明
  • その他の開発活動
  • 歴史

第13章 使用中止薬

• Soticlestat（TAK-935/OV935）：Ovid Therapeutics/Takeda
  • 製品説明
  • その他の開発活動
  • 臨床開発
• AXS-02（ゾレドロン酸二ナトリウム四水和物）：Axsome Therapeutics

第14章 開発報告のない医薬品

• BHV-5000：AstraZeneca/Biohaven Pharmaceutical
  • 製品説明
  • その他の開発活動

第15章 複合性局所疼痛症候群：7つの主要な市場分析

• 主な調査結果
• 市場の展望：主要7ヶ国
• 主要7ヶ国の市場規模
  • 主要7ヶ国の複合性局所疼痛症候群の総市場規模
  • 主要7ヶ国の複合性局所疼痛症候群の総市場規模：治療法別
• 米国の市場規模
• EU4ヶ国および英国の市場規模
• 日本の市場規模

第16章 市場アクセスと償還

第17章 SWOT分析

第18章 アンメットニーズ

第19章 付録

• 参考文献
• 頭字語と略語
• レポートの調査手法

第20章 DelveInsightのサービス内容

第21章 免責事項

第22章 DelveInsightについて

List of Tables

• Table 1: Summary of CRPS, Market, Epidemiology, and Key Events (2019-2032)
• Table 2: Comparison between Signs and Symptoms of CRPS Type 1 and 2
• Table 3: Difference between CRPS Types
• Table 4: Common characteristics of CRPS
• Table 5: Stages of CRPS
• Table 6: Possible mechanisms involved in complex regional pain syndrome
• Table 7: Differential Diagnosis
• Table 8: Technical Investigations Helpful to Exclude a Differential Diagnosis
• Table 9: Differential Diagnosis
• Table 10: Levels of evidence
• Table 11: Revised CRPS criteria adopted by the IASP in 2012
• Table 12: Factors (and factor loadings) resulting from principal components factor analysis of diagnostic and associated signs and symptoms of CRPS
• Table 13: Summary of sensitivity and specificity of the clinical and research criteria
• Table 14: Diagnosis of CRPS - Recommendations
• Table 15: Referral - Recommendations
• Table 16: Surgical practice - Diagnostic Recommendations
• Table 17: Diagnosis of CRPS in emergency medicine - Recommendations
• Table 18: The Veldman criteria
• Table 19: Factors (and factor loadings) resulting from factor analysis of CRPS-related signs/symptoms
• Table 20: Japanese CRPS diagnostic criteria for clinical purposes
• Table 21: Pharmacotherapy guide
• Table 22: Management of suspected or confirmed CRPS - Recommendations
• Table 23: Therapeutic approaches
• Table 24: Yellow Flags
• Table 25: Examples of CRPS-specific rehabilitation techniques
• Table 26: Occupational therapy and physiotherapy- Recommendations
• Table 27: Surgical practice - Management Recommendations
• Table 28: Surgery to amputate the CRPS-affected limb - Recommendations
• Table 29: Management and referral of CRPS in emergency medicine - Recommendations
• Table 30: Management of CRPS in pain clinics
• Table 31: Management of CRPS in pain clinics-referral
• Table 32: Management of patients with CRPS and complex needs
• Table 33: Long-term support in CRPS
• Table 34: Total Prevalent Cases of CRPS in the 7MM (2019-2032)
• Table 35: Total Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Table 36: Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Table 37: Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Table 38: Type-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Table 39: Severity-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Table 40: Treated Cases of CRPS in the 7MM (2019-2032)
• Table 41: Total Prevalent Cases of CRPS in the United States (2019-2032)
• Table 42: Total Diagnosed Prevalent cases of CRPS in the United States (2019-2032)
• Table 43: Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
• Table 44: Age-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
• Table 45: Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
• Table 46: Severity-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
• Table 47: Total Treated cases of CRPS in the United States (2019-2032)
• Table 48: Total Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Table 49: Total Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Table 50: Gender-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Table 51: Age-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Table 52: Type-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Table 53: Severity-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Table 54: Total Treated Cases of CRPS in EU4 and the UK (2019-2032)
• Table 55: Total Prevalent Cases of CRPS in Japan (2019-2032)
• Table 56: Total Diagnosed Prevalent cases of CRPS in Japan (2019-2032)
• Table 57: Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
• Table 58: Age-specific Prevalent Cases of CRPS in Japan (2019-2032)
• Table 59: Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
• Table 60: Severity-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
• Table 61: Treated cases of CRPS in Japan (2019-2032)
• Table 62: Key Cross Competition of Emerging Drugs
• Table 63: Soticlestat (TAK-935/OV935), Clinical Trial Description, 2022
• Table 64: AXS-02 (Disodium Zoledronate tetrahydrate), Clinical Trial Description, 2022
• Table 65: List of CRPS medications with an unknown, terminated or discontinued status, or for which no developmental has been reported
• Table 66: Example of drugs for which the FDA has granted orphan designation but the company has not disclosed any development Activity
• Table 67: 7MM Market Size of CRPS, in USD million (2019-2032)
• Table 68: 7MM Market Size of CRPS by Therapies, in USD Million (2019-2032)
• Table 69: Market Size of CRPS in the United States, USD million (2019-2032)
• Table 70: United States Market Size of CRPS by Therapies, in USD Million (2019-2032)
• Table 71: Market Size of CRPS in EU4 and the UK, in USD million (2019-2032)
• Table 72: Market Size of CRPS by Therapies in EU4 and the UK in USD million (2019-2032)
• Table 73: Market Size of CRPS in Japan, USD million (2019-2032)
• Table 74: Japan Market Size of CRPS by Therapies, in USD Million (2019-2032)

List of Figures

• Figure 1: Epidemiology and Market Methodology
• Figure 2: Understanding of CRPS
• Figure 3: Typical features of a patient with CRPS
• Figure 4: Clinical Manifestations of CRPS and their respective pathophysiological mechanisms
• Figure 5: Model for the development of complex regional pain syndrome (CRPS) from nerve injury
• Figure 6: Speculative model of interacting mechanisms involved in the development of CRPS
• Figure 7: Treatment algorithm
• Figure 8: Four pillars of treatment for CRPS - an integrated interdisciplinary approach
• Figure 9: Pathophysiology and mechanism-based treatment options in CRPS
• Figure 10: CRPS rehabilitation algorithm for occupational therapists and physiotherapists
• Figure 11: Total Prevalent Cases of CRPS in the 7MM (2019-2032)
• Figure 12: Total Diagnosed Prevalent cases of CRPS in the 7MM (2019-2032)
• Figure 13: Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Figure 14: Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Figure 15: Type-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Figure 16: Severity-specific Diagnosed Prevalent Cases of CRPS in the 7MM (2019-2032)
• Figure 17: Treated cases of CRPS in the 7MM (2019-2032)
• Figure 18: Total Prevalent Cases of CRPS in the United States (2019-2032)
• Figure 19: Total Diagnosed Prevalent cases of CRPS in the United States (2019-2032)
• Figure 20: Gender-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
• Figure 21: Age-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
• Figure 22: Type-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
• Figure 23: Severity-specific Diagnosed Prevalent Cases of CRPS in the United States (2019-2032)
• Figure 24: Treated cases of CRPS in the United States (2019-2032)
• Figure 25: Total Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Figure 26: Total Diagnosed Prevalent cases of CRPS in EU4 and the UK (2019-2032)
• Figure 27: Gender-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Figure 28: Age-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Figure 29: Type-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Figure 30: Severity-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK (2019-2032)
• Figure 31: Treated cases of CRPS in EU4 and the UK (2019-2032)
• Figure 32: Total Prevalent Cases of CRPS in Japan (2019-2032)
• Figure 33: Total Diagnosed Prevalent cases of CRPS in Japan (2019-2032)
• Figure 34: Gender-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
• Figure 35: Age-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
• Figure 36: Type-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
• Figure 37: Severity-specific Diagnosed Prevalent Cases of CRPS in Japan (2019-2032)
• Figure 38: Treated cases of CRPS in Japan (2019-2032)
• Figure 39: Market Size of CRPS in the 7MM, in USD million (2019-2032)
• Figure 40: Market Size of CRPS in the 7MM by Therapies, in USD Million (2019-2032)
• Figure 41: Market Size of CRPS in the US, USD million (2019-2032)
• Figure 42: Market Size of CRPS in the United States by Therapies, in USD Million (2019-2032)
• Figure 43: Market Size of CRPS in EU4 and the UK, USD million (2019-2032)
• Figure 44: Market Size of CRPS by Therapies in EU4 and the UK, USD million (2019-2032)
• Figure 45: Market Size of CRPS in Japan, USD million (2019-2032)
• Figure 46: Market Size of CRPS in Japan by Therapies, in USD Million (2019-2032)

DelveInsight's " Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CRPS, historical and forecasted epidemiology as well as the CRPS market trends in the United States, the EU4 and the UK and Japan.

The CRPS market report provides current treatment practices, emerging drugs, CRPS market share of the individual therapies, current and forecasted CRPS market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current CRPS treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, Spain, Italy, and France)
• Japan

Study Period: 2019-2032.

Complex Regional Pain Syndrome (CRPS) Understanding and Treatment Algorithm

The DelveInsight's CRPS market report gives a thorough understanding of the disease. CRPS is a broad term describing excess and prolonged pain and inflammation that follows an injury to an arm or leg or any part of the body. CRPS is clinically characterized by sensory, autonomic, and motor disturbances; it can affect any part of the body, but occurs most often in the extremities. The wrist is most frequently affected after distal radial fractures. Complex regional pain syndrome can develop after different types of injuries, such as sprains and strains, surgeries, fractures, contusions, nerve lesions, stroke, etc.

CRPS has acute (recent, short-term) and chronic (lasting greater than six months) forms. Besides the increased perception of pain, other signs and symptoms that are seen with CRPS, particularly in its early stages are a warm, red, and swollen extremity on the affected side. There are two types of CRPS, Type I occurs after an illness or injury that did not directly damage a nerve in the affected area, and Type II follows a distinct nerve injury. Although the triggers vary, both types of CRPS have the same symptoms and go through the same three stages of the disease. CRPS used to be known as reflex sympathetic dystrophy (RSD) (Type I) and causalgia (Type II). Type I comprises about 90 percent of all cases of CRPS.

There are no objective diagnostic tests for CRPS. Since, its pathophysiologic basis of CRPS is not fully understood, mechanism-based diagnosis is not yet feasible. Therefore, the diagnosis of CRPS is based solely on clinical signs and symptoms. The actual diagnosis of CRPS is made solely based on history and physical examination to determine whether a patient meets CRPS diagnostic criteria (often called the Budapest criteria). Other than this, objective testing (thermography, triple-phase bone scan, quantitative sudomotor axon reflex test, or a trial sympathetic ganglion block) may be used to support a clinical diagnosis.

Treatment

There is currently no cure or any medication that has been approved for CRPS specifically. The goal of currently available treatment is to manage the pain and to increase the mobility of the affected limbs. Effective treatment options in CRPS are limited and consist of both non-invasive and invasive therapies. Physical rehabilitation.

Complex Regional Pain Syndrome (CRPS) Epidemiology

The CRPS epidemiology division provides insights about historical and current CRPS patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted CRPS epidemiology scenario in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.

In 2021, the total prevalent case of CRPS was ~318,500 cases in the 7MM, which are expected to grow during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted CRPS epidemiology [segmented as Total Prevalent Cases of CRPS, Total Diagnosed Prevalent Cases of CRPS, Gender-specific Diagnosed Prevalent Cases of CRPS, Age-specific Diagnosed Prevalent Cases of CRPS, Type-specific Diagnosed Prevalent Cases of CRPS, Severity-Specific Diagnosed Prevalent Cases of CRPS, and Total treated cases of CRPS] in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.

Country Wise- Complex Regional Pain Syndrome (CRPS) Epidemiology

The epidemiology segment also provides the CRPS epidemiology data and findings across the United States, the EU4 and the UK, and Japan.

Complex Regional Pain Syndrome (CRPS) Drug Chapters

The drug chapter segment of the CRPS report encloses the detailed analysis of CRPS marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the CRPS clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for CRPS treatment.

Complex Regional Pain Syndrome (CRPS) Market Outlook

CRPS market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted CRPS market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the CRPS market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the CRPS market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Findings

The CRPS market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of CRPS in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of CRPS was ~USD 58.4 million which is expected to rise during the study period (2019-2032).

The United States Market Outlook

The total market size of CRPS in the United States accounted for ~USD 50.9 million in 2021 which is expected to rise during the study period (2019-2032).

The EU4 Countries and the UK: Market Outlook

In the EU4 and the UK, the total market size of CRPS was ~USD 7 million in 2021, which is expected to rise during the study period (2019-2032).

Japan Market Outlook

In Japan, the total market size of CRPS was ~USD 0.5 million in 2021, which is expected to rise during the study period (2019-2032).

Complex Regional Pain Syndrome (CRPS) Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the CRPS market or expected to get launched in the market during the study period 2019-2032. The analysis covers CRPS market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Complex Regional Pain Syndrome (CRPS) Development Activities

The report provides insights into different therapeutic candidates in the Phase II, and Phase III stages. It also analyses CRPS key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for CRPS emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the CRPS domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or CRPS market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the CRPS Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of CRPS explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the CRPS epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for CRPS are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the CRPS market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global CRPS market.

Report Highlights:

• In the coming years, the CRPS market is set to change due to the upcoming therapies with the novel route of administrations which are under investigation and ongoing research in the CRPS; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence CRPS R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for CRPS. The launch of emerging therapies will significantly impact the CRPS market.
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for CRPS.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Complex Regional Pain Syndrome (CRPS) Report Insights

• Patient Population
• Therapeutic Approaches
• CRPS Pipeline Analysis
• CRPS Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Complex Regional Pain Syndrome (CRPS) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• CRPS Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Complex Regional Pain Syndrome (CRPS) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the CRPS drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the CRPS total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest CRPS market size during the forecast period (2019-2032)?
• At what CAGR, the CRPS market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the CRPS market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the CRPS market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of CRPS?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the UK, and Japan?
• What is the historical CRPS patient pool in seven major markets covering the United States, EU4 and the UK, and Japan?
• What would be the forecasted patient pool of CRPS in seven major markets covering the United States, EU4 and the UK, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about CRPS?
• Out of all 7MM countries, which country would have the highest prevalent population of CRPS during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for CRPS treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of CRPS in the USA, Europe, and Japan?
• What are the CRPS marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of CRPS?
• How many therapies are in-development by each company for CRPS treatment?
• How many are emerging therapies in mid-stage, and late stage of development for CRPS treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CRPS therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CRPS and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Complex Regional Pain Syndrome?
• What are the global historical and forecasted markets of CRPS?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the CRPS market
• To understand the future market competition in the CRPS market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for CRPS in the US, EU4 and the UK, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the CRPS market
• To understand the future market competition in the CRPS market

Table of Contents

1. Key Insights

2. Report Introduction

3. Complex Regional Pain Syndrome (CRPS) Market Overview at a Glance: By Class

• 3.1. Market Share (%) Distribution of CRPS in 2019
• 3.2. Market Share (%) Distribution of CRPS in 2032

4. Executive Summary of CRPS

• 4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

• 6.1. Introduction
• 6.2. Classification
• 6.3. Signs and Symptoms
• 6.4. Clinical Manifestations
• 6.5. Natural Course
  • 6.5.1. Stages
• 6.6. Pathophysiology

7. Diagnosis of CRPS

• 7.1. Investigations
  • 7.1.1. IASP Diagnostic Criteria
• 7.2. Imaging Techniques
• 7.3. Non-invasive imaging techniques
• 7.4. Thermography
• 7.5. Sudomotor Function Tests
• 7.6. Neurophysiological Tests
• 7.7. Examination
• 7.8. Differential diagnosis
• 7.9. Diagnostic Guidelines for CRPS
  • 7.9.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition, 2022
  • 7.9.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults
  • 7.9.3. Japanese CRPS diagnostic criteria

8. Treatment and Management of CRPS

• 8.1. Treatment Guidelines
  • 8.1.1. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition - the USA
  • 8.1.2. UK guidelines for diagnosis, referral, and management in primary and secondary care for CRPS in adults

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale
• 9.3. Epidemiology Scenario: 7MM
  • 9.3.1. Total Prevalent Cases of CRPS in the 7MM
  • 9.3.2. Total Diagnosed Prevalent cases of CRPS in the 7MM
  • 9.3.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the 7MM
  • 9.3.4. Age-specific Diagnosed Prevalent Cases of CRPS in the 7MM
  • 9.3.5. Type-specific Diagnosed Prevalent Cases of CRPS in the 7MM
  • 9.3.6. Severity-specific Diagnosed Prevalent Cases of CRPS in the 7MM
  • 9.3.7. Treated cases of CRPS in the 7MM
• 9.4. The United States Epidemiology
  • 9.4.1. Total Prevalent Cases of CRPS in the United States
  • 9.4.2. Total Diagnosed Prevalent cases of CRPS in the United States
  • 9.4.3. Gender-specific Diagnosed Prevalent Cases of CRPS in the United States
  • 9.4.4. Age-specific Diagnosed Prevalent Cases of CRPS in the United States
  • 9.4.5. Type-specific Diagnosed Prevalent Cases of CRPS in the United States
  • 9.4.6. Severity-specific Diagnosed Prevalent Cases of CRPS in the United States
  • 9.4.7. Treated cases of CRPS in the US
• 9.5. EU4 and the UK Epidemiology
  • 9.5.1. Total Prevalent Cases of CRPS in EU4 and the UK
  • 9.5.2. Total Diagnosed Prevalent cases of CRPS in EU4 and the UK
  • 9.5.3. Gender-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK
  • 9.5.4. Age-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK
  • 9.5.5. Type-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK
  • 9.5.6. Severity-specific Diagnosed Prevalent Cases of CRPS in EU4 and the UK
  • 9.5.7. Treated cases of CRPS in EU4 and the UK
• 9.6. Japan Epidemiology
  • 9.6.1. Total Prevalent Cases of CRPS in Japan
  • 9.6.2. Total Diagnosed Prevalent cases of CRPS in Japan
  • 9.6.3. Gender-specific Diagnosed Prevalent Cases of CRPS in Japan
  • 9.6.4. Age-specific Diagnosed Prevalent Cases of CRPS in Japan
  • 9.6.5. Type-specific Diagnosed Prevalent Cases of CRPS in Japan
  • 9.6.6. Severity-specific Diagnosed Prevalent Cases of CRPS in Japan
  • 9.6.7. Treated cases of CRPS in Japan

10. Patient Journey

11. Key Endpoints in CRPS Clinical Trials

12. Emerging Therapies

• 12.1. Key Cross of Emerging Therapies
• 12.2. Low Dose Naltrexone (LDN): Soin Therapeutics
  • 12.2.1. Product Description
  • 12.2.2. Other Development Activities
  • 12.2.3. History

13. Discontinued drugs

• 13.1. Soticlestat (TAK-935/OV935): Ovid Therapeutics/Takeda
  • 13.1.1. Product Description
  • 13.1.2. Other Developmental Activities
  • 13.1.3. Clinical Development
• 13.2. AXS-02 (Disodium Zoledronate tetrahydrate): Axsome Therapeutics
  • 13.2.1. Product Description
  • 13.2.2. Other Developmental Activities
  • 13.2.3. Clinical Development

14. Drugs for which No development reported

• 14.1. BHV-5000: AstraZeneca/Biohaven Pharmaceutical
  • 14.1.1. Product Description
  • 14.1.2. Other Developmental Activities

15. CRPS: 7 Major Market Analysis

• 15.1. Key Findings
• 15.2. Market Outlook: 7MM
• 15.3. 7MM Market Size
  • 15.3.1. Total Market Size of CRPS in the 7MM
  • 15.3.2. Total Market size of CRPS by Therapies in the 7MM
• 15.4. United States Market Size
  • 15.4.1. Total Market size of CRPS in the United States
  • 15.4.2. Market Size of CRPS by Therapies in the United States
• 15.5. EU4 and the UK Market Size
  • 15.5.1. Total Market size of CRPS in EU4 and the UK
  • 15.5.2. Market Size of CRPS by Therapies in EU4 and the UK
• 15.6. Japan Market Size
  • 15.6.1. Total Market size of CRPS in Japan
  • 15.6.2. Market Size of CRPS by Therapies in Japan

16. Market Access and Reimbursement

17. SWOT Analysis

18. Unmet Needs

19. Appendix

• 19.1. Bibliography
• 19.2. Acronyms and Abbreviations
• 19.3. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight